{"product_id":"daiichisankyo-business-model-canvas","title":"Daiichi Sankyo Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDaiichi Sankyo Business Model Canvas: Strategic Blueprint for Oncology Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Daiichi Sankyo’s business model—this in-depth Business Model Canvas maps value propositions, key partners, revenue streams, and competitive advantages to show how the company scales and innovates in oncology and specialty medicines; perfect for investors, consultants, and entrepreneurs seeking actionable, ready-to-use insights—download the complete Word and Excel files to benchmark and apply these strategies today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Oncology Alliance with AstraZeneca\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe AstraZeneca alliance is Daiichi Sankyo’s cornerstone for FY2025, driving global co-development and co-commercialization of Enhertu and datopotamab deruxtecan across multiple indications; combined 2024 sales of Enhertu reached about $4.0 billion, setting a revenue baseline for expansion.\u003c\/p\u003e\n\u003cp\u003eThe deal leverages shared clinical teams and commercial infrastructure to target US, EU, and APAC markets, aiming to increase combined market penetration by 20–30% in key oncology segments by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal ADC Collaboration with Merck and Co\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2021 global ADC collaboration with Merck \u0026amp; Co. funds development of three ADC candidates, delivering Daiichi Sankyo about $1.5B upfront and potential milestones exceeding $7B; shared late-stage trial costs reduce Daiichi Sankyo’s capex burden and de‑risk timelines. By leveraging Merck’s regulatory footprint across \u0026gt;70 markets and pooled trial enrollment, Daiichi Sankyo targets ADC market leadership by end‑2025, aiming for \u0026gt;30% share in approved ADC revenues.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Biotech Research Consortiums\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo partners with \u0026gt;40 universities and ~60 biotech firms worldwide to source early-stage assets for its proprietary DXd payload linker tech, funding ~¥15.2bn (US$105m) in collaborative R\u0026amp;D in FY2024 to identify novel targets and combination regimens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDaiichi Sankyo partners with specialized contract manufacturing organizations to scale biologics and ADCs production, supporting over 30% year-on-year capacity growth for ADC supply as demand rose in 2024 and meeting ICH and FDA quality standards for global markets.\u003c\/p\u003e\n\u003cp\u003eThis decentralized network reduces regional supply risks and enabled launches in 6 emerging markets in 2024, shortening time-to-market by an average 4–6 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNetwork: specialized CMOs for biologics\/ADCs\u003c\/li\u003e\n\u003cli\u003eCapacity: \u0026gt;30% YOY ADC capacity growth (2024)\u003c\/li\u003e\n\u003cli\u003eQuality: ICH\/FDA-compliant sites\u003c\/li\u003e\n\u003cli\u003eMarket entry: 6 emerging markets (2024)\u003c\/li\u003e\n\u003cli\u003eTime-to-market cut: 4–6 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Ventures for Regional Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn China and parts of Latin America, Daiichi Sankyo forms joint ventures to handle local regulations and speed specialty-medicine distribution, tapping partners’ regional healthcare networks and regulatory expertise; in 2024 these JV routes supported ~18% of emerging-market sales, helping lift group revenue growth in APAC LATAM pockets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJVs navigate licensing, pricing, and import rules\u003c\/li\u003e\n\u003cli\u003ePartners supply hospital access and reimbursement know-how\u003c\/li\u003e\n\u003cli\u003eReduce legal\/cultural entry costs vs direct ops\u003c\/li\u003e\n\u003cli\u003eSupported ~18% of emerging-market revenue in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDaiichi Sankyo’s partnership-fueled surge: Enhertu $4B, $1.5B ADC deal, +30% ADC capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe AstraZeneca and Merck alliances plus 100+ academic\/biotech partners and CMOs underpin Daiichi Sankyo’s FY2024–25 growth: Enhertu sales ~$4.0B (2024), ADC partnership upfronts ~$1.5B, R\u0026amp;D collaborations funded ¥15.2bn (US$105M) in 2024, ADC capacity +30% YOY, JVs drove ~18% of emerging-market sales (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstraZeneca\u003c\/td\u003e\n\u003ctd\u003eEnhertu $4.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck ADC deal\u003c\/td\u003e\n\u003ctd\u003e$1.5B upfront\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D partners\u003c\/td\u003e\n\u003ctd\u003e¥15.2bn (US$105M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eADC capacity +30% YOY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJVs\u003c\/td\u003e\n\u003ctd\u003e18% emerging-market sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Daiichi Sankyo detailing customer segments, channels, value propositions, key activities, resources, partners, cost structure and revenue streams, reflecting real-world operations and strategic priorities to support presentations, investor discussions and internal planning with SWOT-linked insights and competitive differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Daiichi Sankyo’s business model with editable cells—condenses R\u0026amp;D, licensing, and commercial strategy into a one-page snapshot for fast boardroom review and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R and D in ADC Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo’s core activity is advancing its proprietary DXd antibody-drug conjugate (ADC) platform, where R\u0026amp;D spends reached ¥88.4 billion in FY2024 (year ended March 31, 2024); teams optimize linker-payload combos to boost tumor kill and cut systemic toxicity, improving therapeutic index by ~20–30% in recent preclinical models. This specialized R\u0026amp;D underpins its precision-medicine edge and potential mid-term revenue from DS-8201-like assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Clinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManaging a vast portfolio of Phase 1–3 trials is a core operational pillar: as of 2025 Daiichi Sankyo runs over 120 active global trials, coordinating multinational studies across the FDA, EMA and PMDA to support approvals for candidates like DS-1062 and patritumab deruxtecan. These programs require centralized data capture, continuous patient safety monitoring and statistical analyses to demonstrate safety and superiority, with clinical spend of about ¥130 billion (≈$900M) in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Precision Biopharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo runs state-of-the-art biologics and ADC manufacturing sites that are core to its model; in 2024 the company invested ¥83.6 billion (≈$600M) in production capacity and reported \u0026gt;95% batch-release yield for complex biologics.\u003c\/p\u003e\n\u003cp\u003eADC production demands extreme precision to secure stable antibody–payload conjugation; global GMP lines and routine potency\/impurity testing keep product quality and patient safety across markets in 20+ countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Affairs and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDaiichi Sankyo invests in scientific communication—medical affairs spent ~¥48.4bn (¥) on R\u0026amp;D-related outreach in FY2024—to train oncologists and cardiologists on its drugs’ unique mechanisms, improving appropriate use of complex therapies and uptake of ADCs and peptide-based agents.\u003c\/p\u003e\n\u003cp\u003eThese teams deliver peer-reviewed data and real-world evidence to set new oncology and CV care standards, contributing to market access and prescribing confidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 medical affairs-related spend ≈ ¥48.4bn\u003c\/li\u003e\n\u003cli\u003eFocus: antibody-drug conjugates and peptide agents\u003c\/li\u003e\n\u003cli\u003eDelivers clinical data, real-world evidence, HCP training\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDaiichi Sankyo pursues Strategic Lifecycle Management by filing supplemental indications for blockbusters like Enhertu (fam-trastuzumab deruxtecan), targeting new patient populations and earlier lines to extend revenue; Enhertu sales reached ¥214.6bn (FY2024) and supplemental approvals in 2024 expanded HER2-low and gastric indications.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives supplemental NDAs to extend patent value\u003c\/li\u003e\n\u003cli\u003eTargets earlier-line use to increase patient pool\u003c\/li\u003e\n\u003cli\u003eEnhertu: ¥214.6bn sales FY2024, multiple 2024 label expansions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDaiichi Sankyo: Heavy DXd ADC R\u0026amp;D, 120+ Trials, ¥83.6bn Capex, Enhertu ¥214.6bn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo focuses on DXd ADC R\u0026amp;D (R\u0026amp;D spend ¥88.4bn FY2024), global clinical trials (120+ active; clinical spend ≈¥130bn FY2024), ADC manufacturing (¥83.6bn capex 2024; \u0026gt;95% batch yield) and medical affairs (¥48.4bn FY2024) to drive lifecycle management (Enhertu sales ¥214.6bn FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metric FY2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDXd R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e¥88.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials\u003c\/td\u003e\n\u003ctd\u003e120+ trials; ≈¥130bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capex\u003c\/td\u003e\n\u003ctd\u003e¥83.6bn; \u0026gt;95% yield\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical affairs\u003c\/td\u003e\n\u003ctd\u003e¥48.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhertu sales\u003c\/td\u003e\n\u003ctd\u003e¥214.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Daiichi Sankyo Business Model Canvas—not a mockup or sample—and it reflects the full structure, content, and strategic insights included in the final deliverable.\u003c\/p\u003e\n\u003cp\u003eWhen you purchase, you will receive this exact file, fully formatted and editable, so you can immediately use it for analysis, presentations, or strategic planning without any changes.\u003c\/p\u003e\n\u003cp\u003eWe provide full transparency: the previewed pages are taken directly from the final document, and the complete version will be available to download instantly after purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749700743545,"sku":"daiichisankyo-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/daiichisankyo-business-model-canvas.png?v=1772217253","url":"https:\/\/matrixbcg.com\/products\/daiichisankyo-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}